Regenerative medicine company Mesoblast's first-quarter loss has widened by more than 50 per cent to $19.8 million, as it continues to pump money into its chronic heat failure treatment trials.
The company's revenue for the three months to September 30 has plummeted to $395,000, from $7.5 million for the same period of 2015.
Mesoblast's loss rose to 5.24 cents per share, up from 3.94 cents per share last year.
Share
